PMID: 8016Jun 1, 1976

Marrow transplantation in treatment of children with aplastic anaemia or acute leukaemia

Archives of Disease in Childhood
F L JohnsonRainer Storb


Seventy-six patients, aged 2 to 17 years, were treated with bone marrow transplantation for severe aplastic anaemia or acute leukaemia refractory to conventional therapy. 16 of the 22 patients (73%) who received marrow transplantations for aplastic anaemia are surviving, 12 of these for over one year. In acute leukaemia, using preparation with cyclophosphamide and total body irradiation, 8 of 33 patients (24%) receiving allogeneic and 5 of 8 (63%) receiving syngeneic transplantations are continuing in remission from 3 months to beyond 2 years. The longest continuing remission off therapy is now over 4 1/2 years after preparation with total body irradiation. The major causes of failure remain graft-versus-host disease, infection, graft rejection (aplastic anaemia), and leukaemic relapse.


Apr 17, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Apr 24, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Sep 1, 1975·Proceedings of the Royal Society of Medicine·J G Humble, A J Barrett
Apr 22, 1972·Lancet·S Davis, A D Rubin
Jun 17, 1972·Lancet·E D ThomasRainer Storb
Jan 1, 1974·Annual Review of Medicine·P NeimanK G Lerner
Jun 20, 1974·The New England Journal of Medicine·A FeferRainer Storb
Apr 26, 1971·JAMA : the Journal of the American Medical Association·D Pinkel
Jan 1, 1975·Journal of Pediatric Surgery·Melvin D Levine

Related Concepts

Hypoplastic Anemia
Bone Marrow Cells
Graft Rejection
Graft Vs Host Reaction
Lymphoid Leukemia
Remission, Spontaneous
Transplantation, Homologous
Acute Myeloid Leukemia, M1
Bone Marrow Cell Transplantation

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.